| __timestamp | Apellis Pharmaceuticals, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 396000000 |
| Thursday, January 1, 2015 | 13730311 | 364000000 |
| Friday, January 1, 2016 | 22978599 | 376000000 |
| Sunday, January 1, 2017 | 40303878 | 382000000 |
| Monday, January 1, 2018 | 105285576 | 432000000 |
| Tuesday, January 1, 2019 | 220968770 | 457000000 |
| Wednesday, January 1, 2020 | 299921000 | 463000000 |
| Friday, January 1, 2021 | 420869000 | 508000000 |
| Saturday, January 1, 2022 | 387236000 | 539000000 |
| Sunday, January 1, 2023 | 354387000 | 614000000 |
| Monday, January 1, 2024 | 686000000 |
Infusing magic into the data realm
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Zoetis Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Zoetis consistently allocated a significant portion of its budget to R&D, peaking at a 64% increase in 2023 compared to 2014. This steady growth underscores Zoetis's commitment to advancing veterinary medicine.
Conversely, Apellis Pharmaceuticals, a company known for its pioneering work in complement immunotherapy, exhibited a more volatile R&D expenditure pattern. Starting with a modest budget in 2014, Apellis ramped up its R&D spending by an impressive 4,100% by 2021, reflecting its aggressive pursuit of groundbreaking treatments. However, a slight decline in 2023 suggests a strategic recalibration.
These trends highlight the diverse approaches companies take in navigating the competitive pharmaceutical landscape.
Analyzing R&D Budgets: Novo Nordisk A/S vs Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Pfizer Inc. vs Zoetis Inc.
R&D Spending Showdown: Zoetis Inc. vs Teva Pharmaceutical Industries Limited
R&D Spending Showdown: Zoetis Inc. vs Dr. Reddy's Laboratories Limited
R&D Spending Showdown: Zoetis Inc. vs Alkermes plc
Research and Development Investment: Zoetis Inc. vs Vericel Corporation
argenx SE vs Apellis Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Dr. Reddy's Laboratories Limited vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Ascendis Pharma A/S vs Apellis Pharmaceuticals, Inc.
Research and Development Investment: Alpine Immune Sciences, Inc. vs Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.